Numares AG cashes in 20m from EIB
The European Investment Bank (EIB) is going to support the AI-platform of NMR/metabolomics diagnostics company Numares AG to improve disease prediction.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1162 entries already.
Entries by Thomas Gabrielczyk
Amgen wins race of top `22 deals with $26bn for Horizon thx
/in News/by Thomas GabrielczykAccording to Bloomberg, the US biotechnology giant Amgen plans to buy Horizon Therapeutics at a valuation of about $26bn. Overall, the deal corresponds to an enterprise value including debt of […]
European Commission calls for reversal of Illumina’s $7bn Grail merger
/in News/by Thomas GabrielczykThe European Commission has now recommended concrete steps that, while not yet final, would require Illumina to "swiftly" reverse its controversial $7.1bn acquisition of Grail.
BioNTech and Ryvu Therapeutics enter into global collaboration
/in News/by Thomas GabrielczykRenewed focus on cancer: COVID-19 vaccine company BioNTech SE (Nasdaq: BNTX) and Ryvu Therapeutics S.A., located in Krakow (Warsaw Stock Exchange: RVU), a Polish clinical-stage cancer therapeutics development company, announced […]
Amsterdam Neogene Therapeutics aquired by AstraZeneca
/in News/by Thomas GabrielczykAstraZeneca announced an agreement to acquire Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company spezialised in next-generation T-cell receptor therapies (TCR-Ts) that offer a novel cell therapy approach for […]
British AI provider raises $33m in Series A financing
/in News/by Thomas GabrielczykLondon-based computer vision specialist V7 Ltd has baged $33m in Series A financing co-led by AI-focused Radical Ventures and Temasek.
Growing investor interest in biotechnology
/in News/by Thomas GabrielczykLatest investment trends were presented by BIOTECH Insight at the start of the German Equity Forum
C4X Discovery Holdings inks $402m deal with AstraZeneca
/in News/by Thomas GabrielczykC4X Discovery Holdings plc has exclusively licenced its NRF2 Activator programme to AstraZeneca and has got an upfront payment of $2m.
EpiEndo Pharmaceuticals pushes COPD candidate
/in News/by Thomas GabrielczykEpiEndo Pharmaceuticals ehf got the green light for a Phase IIa COPD trial with its non-anbibiotic macrolide EP395
Neotiv GmbH closes 10m seed financing
/in News/by Thomas GabrielczykGerman Neotiv GmbH hat closed a 10m seed financing to speed-up product launch of its early diagnosis app for Alzheimer’s disease